Royalty Pharma plc | Large-cap | Healthcare
$36.14
2.09%
| Royalty Pharma plc Stock Comparison:
Royalty Pharma plc vs VertexRoyalty Pharma plc vs RegeneronRoyalty Pharma plc vs AlnylamRoyalty Pharma plc vs InsmedRoyalty Pharma plc vs IncyteRoyalty Pharma plc vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 2.3B
Operating Income 1.3B 57.10%
Net Income 1.3B 58.79%
EPS (Diluted) $1.91

Balance Sheet Metrics

Total Assets 18.2B
Total Liabilities 7.9B
Shareholders Equity 10.3B
Debt to Equity 0.76

Cash Flow Metrics

Operating Cash Flow 4.3B
Free Cash Flow 2.8B

Revenue & Profitability Trend

Royalty Pharma plc Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 2.3B 2.4B 2.2B 2.3B 2.1B
Cost of Goods Sold - - - - -
Gross Profit - - - - -
Operating Expenses 971.1M 862.4M 1.3B 835.8M 438.8M
Operating Income 1.3B 1.5B 922.9M 1.4B 1.7B
Pre-tax Income 1.3B 1.7B 230.1M 1.2B 1.7B
Income Tax 0 0 0 0 0
Net Income 1.3B 1.7B 230.1M 1.2B 1.7B
EPS (Diluted) $1.91 $2.53 $0.10 $1.49 $2.51

Income Statement Trend

Royalty Pharma plc Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 1.8B 1.3B 2.6B 2.9B 2.7B
Non-Current Assets 16.4B 15.1B 14.3B 14.6B 13.3B
Total Assets 18.2B 16.4B 16.8B 17.5B 16.0B
Liabilities
Current Liabilities 1.3B 161.4M 1.2B 171.2M 307.9M
Non-Current Liabilities 6.6B 6.1B 6.1B 7.1B 5.8B
Total Liabilities 7.9B 6.3B 7.3B 7.3B 6.1B
Equity
Total Shareholders Equity 10.3B 10.1B 9.5B 10.2B 9.9B

Balance Sheet Composition

Royalty Pharma plc Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 1.3B 1.7B 230.1M 1.2B 1.7B
Operating Cash Flow 4.3B 5.0B 2.8B 3.5B 3.9B
Investing Activities
Capital Expenditures - - - - -
Investing Cash Flow -2.7B -2.1B -1.0B -1.9B -5.0B
Financing Activities
Dividends Paid -376.5M -358.3M -333.3M -285.2M -397.8M
Financing Cash Flow 361.1M -2.5B -944.9M 385.1M 1.5B
Free Cash Flow 2.8B 3.0B 2.1B 2.0B 2.0B

Cash Flow Trend

Royalty Pharma plc Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 14.75
Forward P/E 8.23
Price to Book 2.30
Price to Sales 8.98
PEG Ratio 8.23

Profitability Ratios

Profit Margin 48.26%
Operating Margin 94.00%
Return on Equity 18.00%
Return on Assets 7.04%

Financial Health

Current Ratio 1.56
Debt to Equity 77.82
Beta 0.47

Per Share Data

EPS (TTM) $2.45
Book Value per Share $15.72
Revenue per Share $5.09

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
rprx 20.3B 14.75 2.30 18.00% 48.26% 77.82
Vertex 117.0B 32.82 7.09 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Alnylam 40.8B - 353.42 -414.62% -11.49% 2,358.26
Insmed 20.0B - 193.43 -320.20% -265.93% 1,316.96
Incyte 13.0B 336.30 3.55 0.47% 0.48% 1.18

Financial data is updated regularly. All figures are in the company's reporting currency.